Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
AEZS's Cash to Debt is ranked higher than
76% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 108.89 vs. AEZS: No Debt )
AEZS' s 10-Year Cash to Debt Range
Min: 0.76   Max: No Debt
Current: No Debt

Equity to Asset 0.29
AEZS's Equity to Asset is ranked higher than
53% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AEZS: 0.29 )
AEZS' s 10-Year Equity to Asset Range
Min: -0.1   Max: 0.97
Current: 0.29

-0.1
0.97
F-Score: 5
Z-Score: -4.55
M-Score: 0.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -444.96
AEZS's Operating margin (%) is ranked higher than
58% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -66.46 vs. AEZS: -444.96 )
AEZS' s 10-Year Operating margin (%) Range
Min: -1448.42   Max: -8.58
Current: -444.96

-1448.42
-8.58
Net-margin (%) 110.36
AEZS's Net-margin (%) is ranked higher than
99% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -53.69 vs. AEZS: 110.36 )
AEZS' s 10-Year Net-margin (%) Range
Min: -994.25   Max: 110.36
Current: 110.36

-994.25
110.36
ROE (%) 39.94
AEZS's ROE (%) is ranked higher than
98% of the 782 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. AEZS: 39.94 )
AEZS' s 10-Year ROE (%) Range
Min: -278.54   Max: 39.94
Current: 39.94

-278.54
39.94
ROA (%) 11.51
AEZS's ROA (%) is ranked higher than
94% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -18.63 vs. AEZS: 11.51 )
AEZS' s 10-Year ROA (%) Range
Min: -55.21   Max: 14.94
Current: 11.51

-55.21
14.94
ROC (Joel Greenblatt) (%) -2033.75
AEZS's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 840 Companies
in the Global Biotechnology industry.

( Industry Median: -179.37 vs. AEZS: -2033.75 )
AEZS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2033.75   Max: -12.06
Current: -2033.75

-2033.75
-12.06
Revenue Growth (%) -54.30
AEZS's Revenue Growth (%) is ranked higher than
55% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. AEZS: -54.30 )
AEZS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 143.5
Current: -54.3

0
143.5
EBITDA Growth (%) -20.90
AEZS's EBITDA Growth (%) is ranked higher than
64% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: -9.80 vs. AEZS: -20.90 )
AEZS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 177.8
Current: -20.9

0
177.8
EPS Growth (%) -25.90
AEZS's EPS Growth (%) is ranked higher than
64% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. AEZS: -25.90 )
AEZS' s 10-Year EPS Growth (%) Range
Min: 0   Max: 62
Current: -25.9

0
62
» AEZS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

AEZS Guru Trades in Q1 2013

Jim Simons 533,818 sh (+29.06%)
Murray Stahl 17,083 sh (unchged)
» More
Q2 2013

AEZS Guru Trades in Q2 2013

Murray Stahl 17,083 sh (unchged)
Jim Simons 376,650 sh (-29.44%)
» More
Q3 2013

AEZS Guru Trades in Q3 2013

Jim Simons 444,250 sh (+17.95%)
Murray Stahl 17,083 sh (unchged)
» More
Q4 2013

AEZS Guru Trades in Q4 2013

Jim Simons 896,445 sh (+101.79%)
Murray Stahl Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AEZS



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about AEterna Zentaris, Inc.

Billionaires Hold Waning Biotechs 42% Off
Year 2013 has been called the year of the biotech return. According to BioTechNow, the sector is doing better than it has since 2007. One of the highlighted companies today, StemCells Inc. (STEM) just completed its successful IPO last week. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 2.90
AEZS's P/E(ttm) is ranked higher than
97% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. AEZS: 2.90 )
AEZS' s 10-Year P/E(ttm) Range
Min: 2.9   Max: 17.95
Current: 2.9

2.9
17.95
P/B 2.70
AEZS's P/B is ranked higher than
76% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. AEZS: 2.70 )
AEZS' s 10-Year P/B Range
Min: 0.59   Max: 44.68
Current: 2.7

0.59
44.68
P/S 5.11
AEZS's P/S is ranked higher than
73% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. AEZS: 5.11 )
AEZS' s 10-Year P/S Range
Min: 0.56   Max: 7.37
Current: 5.11

0.56
7.37
EV-to-EBIT 7.50
AEZS's EV-to-EBIT is ranked higher than
84% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. AEZS: 7.50 )
AEZS' s 10-Year EV-to-EBIT Range
Min: 2.5   Max: 24.1
Current: 7.5

2.5
24.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 53.50
AEZS's Price/Net Cash is ranked lower than
85% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. AEZS: 53.50 )
AEZS' s 10-Year Price/Net Cash Range
Min: 5.63   Max: 69
Current: 53.5

5.63
69
Price/Net Current Asset Value 17.80
AEZS's Price/Net Current Asset Value is ranked lower than
65% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. AEZS: 17.80 )
AEZS' s 10-Year Price/Net Current Asset Value Range
Min: 4.9   Max: 23
Current: 17.8

4.9
23
Price/Tangible Book 7.60
AEZS's Price/Tangible Book is ranked lower than
55% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. AEZS: 7.60 )
AEZS' s 10-Year Price/Tangible Book Range
Min: 1.67   Max: 9.86
Current: 7.6

1.67
9.86
Price/Median PS Value 0.70
AEZS's Price/Median PS Value is ranked higher than
87% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AEZS: 0.70 )
AEZS' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 11.59
Current: 0.7

0.37
11.59
Price/Graham Number 1.60
AEZS's Price/Graham Number is ranked higher than
80% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. AEZS: 1.60 )
AEZS' s 10-Year Price/Graham Number Range
Min: 1.27   Max: 4.82
Current: 1.6

1.27
4.82
Earnings Yield (Greenblatt) 13.40
AEZS's Earnings Yield (Greenblatt) is ranked higher than
81% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. AEZS: 13.40 )
AEZS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.2   Max: 40.3
Current: 13.4

4.2
40.3
Forward Rate of Return (Yacktman) -150.00
AEZS's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. AEZS: -150.00 )
AEZS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -197.5   Max: -8
Current: -150

-197.5
-8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AEZ.Canada, ET81.Germany
AEterna Zentaris, Inc., is incorporated on September 12, 1990 under the Canada Business Corporations Act (the CBCA) and continues to be governed by the CBCA. The Company is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. Its pipeline encompasses compounds at all stages of development from drug discovery through to marketed products. Its oncology pipeline also encompasses other earlier-stage programs, including AEZS-112, an oral anticancer agent which involves three mechanisms of action such as tubulin, topoisomerase II and angiogenesis inhibition which has completed a Phase 1 trial in advanced solid tumors and lymphoma. Additionally, several novel targeted anticancer candidates such as AEZS-120, a live recombinant oral tumor vaccine candidate, as well as PI3K/Erk inhibitors, including AEZS-129, AEZS-134 and AEZS-136, are currently in preclinical development. In endocrinology, the Company is preparing the filing of an NDA in the U.S. for the registration of AEZS-130, an oral ghrelin agonist, as a diagnostic test for adult growth hormone deficiency (AGHD). A Phase 3 trial under a SPA with the FDA has been completed in this indication. Furthermore, AEZS-130 is in a Phase 2A trial for the treatment of cancer-induced cachexia.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide